within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01C_AgentsAgainstLeishmaniasisAndTrypanosomiasis.P01CX03_Eflornithine;

model Eflornithine
  extends Pharmacolibrary.Drugs.ATC.P.P01CX03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>P01CX03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Eflornithine is an antiprotozoal drug primarily used in the treatment of African trypanosomiasis (sleeping sickness), especially caused by Trypanosoma brucei gambiense. It inhibits ornithine decarboxylase, an enzyme involved in polyamine synthesis. Eflornithine is approved for this indication and is on the WHO Essential Medicines List. It is also used topically for reduction of unwanted facial hair in women (not described here).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for intravenous eflornithine in adult patients with African trypanosomiasis. Data reported for both sexes, typical adult weight range, with normal renal function.</p><h4>References</h4><ol><li><p>Boberg, M, et al., &amp; Ashton, M (2021). Enantiospecific antitrypanosomal in vitro activity of eflornithine. <i>PLoS neglected tropical diseases</i> 15(7) e0009583–None. DOI:<a href=\"https://doi.org/10.1371/journal.pntd.0009583\">10.1371/journal.pntd.0009583</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34252098/\">https://pubmed.ncbi.nlm.nih.gov/34252098</a></p></li><li><p>Amilon, C, et al., &amp; Jansson-Löfmark, R (2022). Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy. <i>The AAPS journal</i> 24(3) 48–None. DOI:<a href=\"https://doi.org/10.1208/s12248-022-00693-2\">10.1208/s12248-022-00693-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35338410/\">https://pubmed.ncbi.nlm.nih.gov/35338410</a></p></li><li><p>Jansson, R, et al., &amp; Ashton, M (2008). Enantioselective and nonlinear intestinal absorption of eflornithine in the rat. <i>Antimicrobial agents and chemotherapy</i> 52(8) 2842–2848. DOI:<a href=\"https://doi.org/10.1128/AAC.00050-08\">10.1128/AAC.00050-08</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18519728/\">https://pubmed.ncbi.nlm.nih.gov/18519728</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Eflornithine;
